Table 1.
The comparison of baseline characteristics of the patients in training and validation cohorts.
| Variables | Training Cohort (n = 519) | Validation Cohort (n = 259) | p Value |
|---|---|---|---|
| DPN, no. (%) | 341 (65.7%) | 187 (72.2%) | 0.081 |
| Age (years) | 57.76 ± 12.95 | 58.97 ± 12.49 | 0.265 |
| Male, no. (%) | 334 (64.4%) | 159 (61.4%) | 0.465 |
| Smoking, no. (%) | 180 (34.7%) | 77 (29.7%) | 0.193 |
| Hypertension, no. (%) | 266 (51.3%) | 143 (55.4%) | 0.307 |
| Dyslipidemia, no. (%) | 168 (32.4%) | 78 (30.1%) | 0.579 |
| Duration (years) | 10 (4–12) | 10 (5–15) | 0.061 |
| BMI (kg/m2) | 24.21 ± 3.49 | 24.23 ± 3.60 | 0.803 |
| FPG (mmol/L) | 7.95 ± 2.90 | 8.10 ± 3.69 | 0.813 |
| UA (umol/L) | 329.04 ± 101.10 | 326.47 ± 98.71 | 0.748 |
| TC (mmol/L) | 4.79 ± 1.35 | 4.81 ± 1.48 | 0.835 |
| TG (mmol/L) | 1.91 ± 1.74 | 1.89 ± 1.47 | 0.481 |
| HDL-C (mmol/L) | 1.02 ± 0.29 | 1.05 ± 0.43 | 0.753 |
| LDL-C (mmol/L) | 2.61 ± 0.98 | 2.58 ± 1.03 | 0.629 |
| FIB (g/L) | 3.79 ± 1.24 | 3.71 ± 1.05 | 0.950 |
| NLR | 2.36 ± 1.41 | 2.45 ± 1.62 | 0.438 |
| PLT (×109/L) | 221.10 ± 64.93 | 222.26 ± 61.99 | 0.809 |
| HbA1c (%) | 9.32 ± 2.38 | 9.42 ± 2.82 | 0.940 |
| TSH (mIU/L) | 1.34 (0.91–2.03) | 1.31 (0.86–1.92) | 0.124 |
| FT4 (pmol/L) | 11.24 ± 2.33 | 11.34 ± 2.11 | 0.423 |
| FT3 (pmol/L) | 4.64 ± 0.79 | 4.67 ± 0.84 | 0.568 |
DPN, Diabetic peripheral neuropathy; BMI, body mass index; FPG, fasting plasma glucose; UA, uric acid; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FIB, fibrinogen; NLR, the ratio of neutrophil count to lymphocyte count; PLT, platelet; HbA1c, hemoglobin A1c; TSH, thyroid stimulating hormone; FT4, free thyronine; FT3, free triiodothyronine.